The FDA accepted under a priority review status Insmed's Alis, or amikacin liposome inhalation suspension, as a treatment for patients with nontuberculous mycobacterial lung disease caused by the Mycobacterium avium complex. The agency set a PDUFA date of Sept. 28.
Insmed's lung infection drug gets FDA priority review status
Sign up for BIO SmartBrief
Biotechnology industry news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.